About VeonGen
VeonGen Therapeutics (formerly ViGeneron) is built on our passion for bringing gene therapy innovations and advances to people in need. Our proprietary science solves key limitations of current gene therapy approaches.
At VeonGen, we are dedicated to developing innovative gene therapies to treat ophthalmologic diseases with high unmet medical need, as well as partnering with leading biopharmaceutical companies in other disease areas.
The company's pipeline is based on three unique and proprietary adeno-associated virus (AAV) technology platforms. The first, the vgAAV gene therapy vector platform, enables superior transduction efficiency and intravitreal, less invasive treatment delivery. The second, the VgRNA REVeRT vector platform, targets diseases caused by mutations in large genes. The third enables bidirectional modulation of multiple genes.
VeonGen Therapeutics (formerly ViGeneron) was founded in 2017 as a spin-off from Ludwig-Maximilians-Universität (LMU) Munich. The company's founding team includes highly experienced executives and internationally renowned experts with proven track records in the development of retinal gene therapy programs from discovery to the clinical phase.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of company presentation. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
- Focus : Manufacturer
- Industry : Biotechnology
Here you will find VeonGen GmbH
Last viewed contents
Abcam plc - Cambridge, United Kingdom
Ocean Optics B. V. - Ostfildern, Germany
Gebr. SCHMID GmbH - Freudenstadt, Germany
Heraeus expands capacity for platinum-based active pharmaceutical ingredients to treat cancer